Back to news

Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+

Globe Newswire•18/11/2026•08:01 ET
1

Key Highlights

  • ➤Total revenue $64.1 million, up ~228% YoY, exceeded guidance
  • ➤IM8 revenue $62.9 million, up ~266% YoY, marked seventh consecutive record quarter
  • ➤27,000 early IM8 customers returned approximately 4.1x acquisition cost in gross profit
  • ➤Second-half 2026 Adjusted EBITDA loss forecast widened to $30–35 million from $8–12 million
  • ➤FY2027 IM8 revenue guidance reaffirmed at $400 million or more

Expert Statements

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“This was a record quarter, with revenue above the top of our guidance, and our case for investing in IM8 has never been clearer.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“So we are investing more.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“The 27,000 customers we acquired in our first full quarter have already returned about 4.1 times their acquisition cost in gross profit, in under two years, buying only our core products.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“That is gross profit already collected, not a forecast, and three to one is the benchmark subscription businesses are widely measured against.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“The next 91,000 customers are on pace to pass it in early 2027.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“Customers we acquire at today’s cost are earning it back in about six months, and independent card data shows our customers staying longer than those of the three leading brands we are compared with, as we detail in our Shareholder Letter and Investor Presentation.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“Returns like these are why we now expect a second-half Adjusted EBITDA loss of $30 to $35 million.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“That is our choice.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“We will keep investing at this pace for as long as the returns hold, and not a day longer.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“We are making that choice from strength.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“That frees our own capital for what keeps customers with us: new products, three clinical trials now underway, and inventory built ahead of demand.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“If we stopped acquiring new customers tomorrow, our existing subscribers alone would make this company profitable on an Adjusted EBITDA basis.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“We keep going because every customer we bring in today becomes more valuable with each product and channel we add.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“In under two years we have taken IM8 from nothing to an Annualized Revenue Run-Rate of about $284 million, which we believe no brand in this category has done before.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“2027 will be bigger still: a core business we expect to exceed $400 million of revenue, and on top of it IM8 Hydration in the first quarter, Care Bears by IM8 in the second quarter, and our first retail shelves and China by the end of the year, none of which is in that number.”

Danny Yeung, Co-Founder and CEO of Prenetics and IM8

“This is what I have lived for.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“Six months into my role at IM8, what stands out is how well the numbers hold up when you take them apart, cohort by cohort.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“It is rare to see growth at this rate with returns that can be measured this precisely.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“This quarter, revenue came in above the top of the range we gave in August, Customer Acquisition Cost declined for the second consecutive quarter while we spent more, and Adjusted EBITDA improved to a loss of $12.7 million, or 20% of revenue, from 39% in the second quarter.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“Our cash and current financial assets grew during a quarter of record investment.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“We now expect a second-half Adjusted EBITDA loss of $30 to $35 million, compared with the $8 to $12 million we guided to in August.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“At the midpoint of our guidance ranges, that is about 23% of second-half revenue, compared with about 30% in the first half.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“It is a deliberate increase in customer acquisition investment, 70% of which is financed by our General Catalyst facility.”

Brian Rosin, Chief Financial Officer Designate of Prenetics

“On everything I have seen in six months here, the case for making that investment is strong, and I am excited about what is ahead.”

— Total revenue of $64.1 million, up ~228% YoY (~3.3x); above the Company’s guidance of $63–64 million

— IM8 revenue of $62.9 million, up ~266% YoY (~3.7x); above the Company’s guidance of $61.5–62.5 million, marking the seventh consecutive record quarter

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in